Short Bowel Syndrome
Conditions
Brief summary
A new Enteric-Coated Cholestyramine (ECC) capsule has been developed to manage diarrhea associated with Short Bowel Syndrome (SBS) in adults. The formulation is expected to release cholestyramine in the remaining segment of the small intestine in SBS patients, thus binding bile acids after fat digestion, but before induction of diarrhea in the colon. The delayed-release profile is also expected to help reduce the potential for drug-drug interactions occurring in the proximal small intestine. Two doses of ECC will be studied for efficacy, safety and tolerability in this Phase IIa trial.
Detailed description
A new Enteric-Coated Cholestyramine (ECC) capsule has been developed to manage diarrhea associated with Short Bowel Syndrome (SBS). SBS is usually caused by the significant resection or loss of function of the ileum, leading to reduced reabsorption of bile acids and subsequent osmotic diarrhea. The new ECC formulation could release cholestyramine in the remaining segment of the small intestine in SBS patients, delivering and binding bile acids before they induce diarrhea in the colon. The proposed advantages of this formulation are: a) to prevent drug-drug interactions in the proximal GI tract, b) to preserve the fat digestive properties of bile acids in the duodenum and 3) to offer a more palatable dosage form to patients. Moreover, since distal delivery of cholestyramine is expected to be more effective in diarrhea prevention/reduction in SBS, lower doses than the ones used with non-enteric coated cholestyramine may be sufficient. Two doses of ECC will be studied for efficacy, safety and tolerability in well-defined non fully-colectomized, adult SBS patients suffering from diarrhea.
Interventions
DRUGEnteric-Coated Cholestyramine (ECC) Capsule
Enteric-Coated Delayed Release Cholestyramine Capsules
DRUGPlacebo
Enteric-Coated Delayed Release Placebo Capsules
Sponsors
Pharmascience Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
This study will be fully blinded, using the double dummy technique (combination of active ECC capsules and matching placebo in the low dose treatment arm).
Intervention model description
Multiple-center, randomized, double-blind, double dummy, 2-period, 2-sequence cross-over design
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Adult, ambulatory male and female subjects 2. Provision of signed and dated informed consent form (ICF) 3. Age ≥ 18 years and ≤ 80 years 4. Stable SBS of: 1. Non-surgical origin; OR 2. Surgical origin where the last surgical ileal resection was performed at least 6 months prior to enrolment 5. Partial, Home Parenteral Nutrition and/or parenteral fluids are allowed, at a maximum frequency of 6 times a week throughout the trial, as long as the regimen has been stable for at least 2 weeks prior to screening and is expected to remain unchanged during the study 6. At least 50 % of the colon being intact 7. Intact duodenum 8. BMI ≥ 18 9. Presence of stable chronic diarrhea for at least 3 months prior to enrolment as evidenced by medical history 10. Presence of stable chronic diarrhea during the 2-week screening diary period before randomization, as evidenced by completion of a screening diary demonstrating: 1. Mean daily production of at least 3 soft or watery stools (BSFS scores 6 or 7); or 2. More than 3 bowel movements per day on average with \>25% of them being BSFS type 6 or 7 11. Stated willingness and ability to comply with all study procedures, including daily recording of bowel movements and BSFS in the patient diaries, and availability for the duration of the study 12. Clinical laboratory values within the laboratory's stated normal range; if not within this range, they must be without clinical significance, as determined by the investigator 13. Female subjects must meet one of the following criteria: a) Participant is of childbearing potential and agrees to use one of the accepted contraceptive regimens from at least 30 days prior to the first study treatment administration through to at least 30 days after the last dose of the study treatment. An acceptable method of contraception includes one of the following: 1. Abstinence from heterosexual intercourse 2. Systemic contraceptives (combined birth control pills, injectable/implant/insertable hormonal birth control products, transdermal patch) 3. Intrauterine device (with or without hormones) 4. Condom with spermicide b) Participants of non-childbearing potential, defined as surgically sterile (i.e. has undergone complete hysterectomy or bilateral oophorectomy) or is in a menopausal state (i.e. at least 1 year without menses prior to the first study drug administration) are eligible
Exclusion criteria
1. Patients with known or suspected intestinal strictures of clinical relevance as judged by the Investigator 2. Active inflammatory bowel disease (IBD) or fistula during the screening period as judged by the Investigator 3. Crohn's disease patients not being in clinical remission for the last 12 weeks prior to randomization 4. Diarrhea caused by other causes than SBS 5. Presence of clinically significant steatorrhea, requiring pancreatic enzymes supplementation 6. Presence of complete biliary obstruction 7. Presence of active cancer (except resected cutaneous basal or squamous cell carcinoma and except in situ cervical cancer) and/or need to receive chemotherapy or radiotherapy during the study 8. History of allergic reaction to cholestyramine or any excipient of the investigational drug product or placebo, or packaging components 9. Females who are lactating at screening 10. Females who are pregnant according to the pregnancy test at screening or prior to the first study treatment administration 11. Significant history (at least 3 consecutive months in the year prior to Screening) of drug dependency or alcohol abuse (\> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic) 12. Subjects who took an Investigational Product (IP) in the 30 days prior to the first study drug administration 13. Any other clinically significant condition that is considered by the principal investigator as being susceptible to put the patient at greater safety risk, influence response to study product, or interfere with study assessments.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in the Weekly Frequency of Bowel Movements Measured Between Baseline and the Second Week of Treatment | Baseline and Week 2 of treatment (Days 8 to 14, and Days 36 to 42) | Change in the weekly frequency of bowel movements measured between baseline and the second week of treatment. Baseline is defined as the second week of screening for treatment period 1 and second week of washout for treatment period 2. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Total Number of Bowel Movements for the Whole 2-week Treatment Period | Days 1 to 14 and Days 29 to 42 | — |
| Mean Daily Stool Form Score According to the BSFS (Bristol Stool Form Scale), Measured During the Second Week of Treatment | Days 8 to 14, and Days 36 to 42 | The BSFS classifies the form of human feces into seven categories (Type 1 to Type 7) based on stool shape and consistency. Types or scores of 1 and 2 indicate constipation, with 3 and 4 being the ideal stools as they are easy to defecate while not containing excess liquid, 5 tending towards diarrhea, and 6 and 7 indicate diarrhea. |
| Mean Daily Dose of Loperamide in mg, if Used, During the Second Week of Treatment | Days 8 to 14, and Days 36 to 42 | — |
Countries
Poland
Participant flow
Pre-assignment details
This was a multiple center, randomized, double-blind, double dummy, 2-period, 2-sequence cross-over study design planned to evaluate 18 patients at three study centers. Due to early study termination only 13 patients were randomized and received treatment with ECC.
Participants by arm
| Arm | Count |
|---|---|
| Intent-to-Treat (ITT Population) Demographics and baseline characteristics were assessed for the overall ITT Population | 13 |
| Total | 13 |
Baseline characteristics
| Characteristic | Intent-to-Treat (ITT Population) |
|---|---|
| Age, Continuous | 54.9 years STANDARD_DEVIATION 15.98 |
| Body Mass Index (BMI) | 24.1 kg/m^2 STANDARD_DEVIATION 3.84 |
| Race/Ethnicity, Customized Asian | 0 Participants |
| Race/Ethnicity, Customized Black | 0 Participants |
| Race/Ethnicity, Customized Caucasian | 13 Participants |
| Race/Ethnicity, Customized Other | 0 Participants |
| Region of Enrollment Poland | 13 participants |
| Sex: Female, Male Female | 6 Participants |
| Sex: Female, Male Male | 7 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 13 | 0 / 13 |
| other Total, other adverse events | 3 / 13 | 4 / 13 |
| serious Total, serious adverse events | 0 / 13 | 0 / 13 |
Outcome results
Primary
Change in the Weekly Frequency of Bowel Movements Measured Between Baseline and the Second Week of Treatment
Change in the weekly frequency of bowel movements measured between baseline and the second week of treatment. Baseline is defined as the second week of screening for treatment period 1 and second week of washout for treatment period 2.
Time frame: Baseline and Week 2 of treatment (Days 8 to 14, and Days 36 to 42)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Low Dose ECC Regimen | Change in the Weekly Frequency of Bowel Movements Measured Between Baseline and the Second Week of Treatment | -11.5 Weekly bowel movements | Standard Deviation 11.38 |
| High Dose ECC Regimen | Change in the Weekly Frequency of Bowel Movements Measured Between Baseline and the Second Week of Treatment | -13.4 Weekly bowel movements | Standard Deviation 9.73 |
Secondary
Mean Daily Dose of Loperamide in mg, if Used, During the Second Week of Treatment
Time frame: Days 8 to 14, and Days 36 to 42
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Low Dose ECC Regimen | Mean Daily Dose of Loperamide in mg, if Used, During the Second Week of Treatment | 72.9 mg | Standard Deviation 43.05 |
| High Dose ECC Regimen | Mean Daily Dose of Loperamide in mg, if Used, During the Second Week of Treatment | 68.9 mg | Standard Deviation 53.19 |
Secondary
Mean Daily Stool Form Score According to the BSFS (Bristol Stool Form Scale), Measured During the Second Week of Treatment
The BSFS classifies the form of human feces into seven categories (Type 1 to Type 7) based on stool shape and consistency. Types or scores of 1 and 2 indicate constipation, with 3 and 4 being the ideal stools as they are easy to defecate while not containing excess liquid, 5 tending towards diarrhea, and 6 and 7 indicate diarrhea.
Time frame: Days 8 to 14, and Days 36 to 42
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Low Dose ECC Regimen | Mean Daily Stool Form Score According to the BSFS (Bristol Stool Form Scale), Measured During the Second Week of Treatment | 3.6 Score on BSFS scale | Standard Deviation 1.42 |
| High Dose ECC Regimen | Mean Daily Stool Form Score According to the BSFS (Bristol Stool Form Scale), Measured During the Second Week of Treatment | 3.7 Score on BSFS scale | Standard Deviation 1.76 |
Secondary
Total Number of Bowel Movements for the Whole 2-week Treatment Period
Time frame: Days 1 to 14 and Days 29 to 42
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Low Dose ECC Regimen | Total Number of Bowel Movements for the Whole 2-week Treatment Period | 52.5 Bowel movements | Standard Deviation 20.12 |
| High Dose ECC Regimen | Total Number of Bowel Movements for the Whole 2-week Treatment Period | 55.1 Bowel movements | Standard Deviation 25.18 |